Share Name Share Symbol Market Type Share ISIN Share Description
Hutchison China Meditech LSE:HCM London Ordinary Share KYG4672N1016 ORD USD1
  Price Change % Change Share Price Shares Traded Last Trade
  +15.00p +0.32% 4,775.00p 68,236 09:00:05
Bid Price Offer Price High Price Low Price Open Price
4,750.00p 4,800.00p 4,775.00p 4,760.00p 4,775.00p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 178.6 -39.6 -31.8 - 3,174.64

Hutchison China Meditech (HCM) Latest News

More Hutchison China Meditech News
Hutchison China Meditech Takeover Rumours

Hutchison China Meditech (HCM) Share Charts

1 Year Hutchison China Meditech Chart

1 Year Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

1 Month Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Intraday Hutchison China Meditech Chart

Hutchison China Meditech (HCM) Discussions and Chat

Hutchison China Meditech Forums and Chat

Date Time Title Posts
20/5/201817:29(Chi-Med)Hutchinson China Meditech Limited1,450
13/6/201707:54Hutchison China Meditech- CHARTS AND DISCUSSION74

Add a New Thread

Hutchison China Meditech (HCM) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2018-05-22 16:27:144,785.003,000143,550.00O
2018-05-22 16:15:004,780.005,000239,000.00O
2018-05-22 16:15:004,780.005,000239,000.00O
2018-05-22 15:32:454,800.001,00048,000.00O
2018-05-22 15:16:194,790.002,00095,800.00O
View all Hutchison China Meditech trades in real-time

Hutchison China Meditech (HCM) Top Chat Posts

Hutchison China Meditech Daily Update: Hutchison China Meditech is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchison China Meditech was 4,760p.
Hutchison China Meditech has a 4 week average price of 4,625p and a 12 week average price of 3,985p.
The 1 year high share price is 5,920p while the 1 year low share price is currently 3,055p.
There are currently 66,484,620 shares in issue and the average daily traded volume is 27,986 shares. The market capitalisation of Hutchison China Meditech is £3,174,640,605.
nerdofsteel: Mark Slater has made partial disposals regularly over the past 10 years as the share price has increased, so as not to go over the 10% regulatory threshold. That is a nice problem for a Fund Manager to have.
nerdofsteel: I notice we are in the Investors Chronicle AIM top 10 picks for 2018 4. Hutchison China MediTech It has been 30 years since a Chinese company last launched a globally commercialised medicine, but Hutchison China Meditech (HCM) is on the cusp of changing that. Its novel cancer drug, Savolitinib, is in the closing stages of a final phase clinical trial which analysts think has a 75 per cent chance of success. If it gets the green light from regulators, Savolitinib will be used to treat kidney cancer, while further testing might give it the potential to be used in non-small cell lung cancer patients as well. After 20 years of steady investment in research and development, clinical success has come thick and fast in the last 18 months. Aside from the Savolitinib trial, Chi-Med has seven final phase programmes ongoing in four different drugs which analysts think could generate peak annual sales of $7.6bn. The most advanced of these is colorectal cancer treatment, Fruquintinib, which could be launched in China later this year. Arguably more important is the depth in the early- and mid-stage pipeline, which gives the group an excellent long-term outlook. There are five oncology medicines currently undergoing early-stage human trials, which should be launched between 2020 and 2023 and a further five in pre-clinical studies. Chi-Med is certainly not a one-trick pony looking to develop and divest novel drugs, but a fast-growing commercial biotech company with a long line of new medicines which should keep the top line growing for many years. The group£s commercial arm in China is well established and will provide an excellent platform to sell medicines once they gain approval. It also generates cash to fund the drug development branch, while a recent $293m fundraise from the group£s Nasdaq investors has strengthened the balance sheet. The innovation division also earns money for Chi-Med in the form of milestone payments, notably from big pharma groups Eli Lilly and AstraZeneca, which the group has partnered with to develop Fruquintinib and Savolitinib, respectively. The group will continue to receive one-off payments throughout the development stage and then royalties on the drugs£ sales. Profits may still be some way off (which makes valuing Chi-Med very difficult), but we think the plethora of potential drug launches should give plenty of firepower to the share price in the next few years. The Chinese healthcare market is also becoming increasingly attractive as doctors and pharma companies seek to match their western counterparts. Buy. MB
dbadvn: Had a very interesting meeting with the CFO . They are certainly sticking to plan and gearing up for European/US sales independently of whatever happens with Lilley etc. Making all the right noises on Clinical/ Sales teams/ Branding/ Competition and realistic on timescale. Not defending the fact that the recent cash raise was basically opportunistic use of perfect market conditions . Looking to be cash flow positive within 5 years ( doe not exclude more cash raising depending on opportunities). The positive "elephant in the room" is the $50bn potential of HMPL 523 in the immunology market. Although still at the early stages HCM seem to have the lead here and only Gilead as competition. Short term lack of news flow may see the share price drift but medium and long term potential probabilities of success are increasing . At some point the US market will start to valur HCM in the same way as the US Biotechs ( less the takeover premium perhaps ) .At that point the share price will react strongly . When that happens is anyones guess so I for one am staying invested long term
nerdofsteel: mad - agree 100%, and if you look back at the share price in London over the last 10 years you see sometimes quite lengthy periods where the share price is stagnant, followed by sharp increases, then further stagnation
reptile3: Short interest on the NASDAQ is 326.25k shares which I assume is significant and affecting the share price today.
its the oxman: Little bit of strength returning to the share price?
lauders: Well I thought the RNS today was worth a bit of reaction re: the share price. Obviously not but odd it is not showing in the header: Https://
lauders: Thank you Nerdofsteel. Appreciate the feedback. Your reply makes sense, so it could be a win-win. If positive the share price will likely increase in turn, if negative it will drop but allow those with the future in mind to add more and benefit from marketing freely and perhaps penning an alternative deal. Can Lilly risk the latter? Now let's just see what the Nasdaq does today. If it is a good day the share price will recover. If not we could be going down again.
lauders: Perhaps foolish but I bought in on this dip! Seems too steep so either bad news is on the way or it is just a major correction on a frothy share price and is due a change in direction soon. Obviously I am hoping for the latter! RSI makes it a buy at least. One of the things I found during my due diligence into HCM: Https:// I wasn't aware of the video before even if it is a bit dated now.
mad foetus: Amazing that nobody notices this company - incredible share price record, incredible prospects, massive positive response to fund raising, share price sharply up and nobody notices. LOL!
Hutchison China Meditech share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:32 V: D:20180523 01:40:26